0001209191-19-058104.txt : 20191126
0001209191-19-058104.hdr.sgml : 20191126
20191126161510
ACCESSION NUMBER: 0001209191-19-058104
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191125
FILED AS OF DATE: 20191126
DATE AS OF CHANGE: 20191126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lee Sung
CENTRAL INDEX KEY: 0001793200
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 191251037
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-11-25
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001793200
Lee Sung
7000 MARINA BLVD.
BRISBANE
CA
94005
0
1
0
0
EVP, Chief Financial Officer
Common Stock
2019-11-25
4
A
0
43750
0.00
A
43750
D
Stock Option (Right to Buy)
10.35
2019-11-25
4
A
0
262000
0.00
A
2029-11-24
Common Stock
262000
262000
D
Includes 43,750 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on November 25, 2019. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service with the Issuer through such date.
One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the November 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
/s/ Matthew Colvin, Attorney-in-Fact for Sung Lee
2019-11-26